

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

CURIUM US LLC,

Petitioner,

v.

**UNIVERSITÄT HEIDELBERG AND THE EUROPEAN ATOMIC
ENERGY COMMUNITY (EURATOM), REPRESENTED BY THE
EUROPEAN COMMISSION,**

Patent Owners

Case No. IPR2025-01582

Patent No. 10,980,901 B2

DECLARATION OF MIRJAM WEIS

1. I, Mirjam Weis, submit this declaration in support of the above-referenced proceeding.
2. I have personal knowledge of the matters set forth in this declaration unless otherwise indicated.
3. I am a Technical Assistant in the lab of Professor Alfred Morgenstern at the European Commission's JRC in Karlsruhe, Germany.
4. The statements in this declaration are true and correct to the best of my knowledge and belief and are based on my own personal education, training, and experience unless otherwise indicated.

I. PERSONAL BACKGROUND

5. I received my two-year certificate as a Biological Technical Assistant (BTA) at Naturwissenschaftliches Technikum Dr.Künkele, a technical school in Landau, Germany. After certifying, I worked at Heidelberg University. In September 2003, I joined Professor Morgenstern's laboratory at the European Commission's JRC in Karlsruhe, Germany where I am part of the Targeted Alpha Immunotherapy Group. I have been there ever since.
6. I have been an author on two papers, the 2016 Journal of Nuclear Medicine publication, *²²⁵Ac-PSMA-617 for PSMA-Targeted α -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer*, 57 J. Nuclear Medicine 1941

(2016) with Dr. Clemens Kratochwil as the first author (for brevity, I will refer to this as “Kratochwil 2016”) and *In vitro evaluation of ^{225}Ac -DOTA-substance P for targeted alpha therapy of glioblastoma multiforme*, 92(1) Chem Biol Drug Des. 1344 (2018).

THE '901 PATENT AND THE 2016 PAPER

7. In Professor Morgenstern’s lab, my job was initially to perform cell culture care and experiments with cell lines. I also perform the day-to-day routine lab care that keeps a lab running, like maintaining the liquid nitrogen, organizing the lab tools, and putting in supply orders. Later, I organized shipments of radioactive materials, like the ^{225}Ac compounds, from our lab to hospitals and matters related to that.
8. My duties also include performing cellular experiments with radioactive materials at Professor Morgenstern’s direction. He will design the experiments and I will perform them according to his instructions. If there are changes in the experiment – for example proposing a new experimental protocol based on the previous results – Professor Morgenstern will decide that protocol as well.
9. I have done cellular experiments with the ^{225}Ac -PSMA-617 looking at cell death at Professor Morgenstern’s instruction. I was not involved in the creation or design of the ^{225}Ac -PSMA-617 compound. I did not know anything about the

dosing or methodology of using the ^{225}Ac -PSMA-617 for any treatments. I do not do any other work with the radioactive materials.

10. Although I was included as a co-author on the Kratochwil 2016 paper, I did not provide any data to the paper. Data from my cellular work was included in my other paper in 2018, "In vitro evaluation of ^{225}Ac -DOTA-substance P for targeted alpha therapy of glioblastoma multiforme."
11. In the 2014 to 2016 time frame, I was in Professor Morgenstern's lab doing cell culture care and experiments and routine lab work. I did cell culture studies with the ^{225}Ac -PSMA-617 looking at their ability to kill cells at different concentrations. As explained above, these studies were designed by Professor Morgenstern or others in the group. At that time, I did not organize the radioactive shipments. My other colleagues have done the shipping at that time. I do not remember having any direct interaction with Dr. Kratochwil at that time. My primary contribution to the paper was carrying out routine lab work to keep Professor Morgenstern's lab running.
12. I do not believe that I qualify as an inventor on the U.S. Patent No. 10,980,901. Everything I know about the ^{225}Ac -PSMA-617 molecule and its use originated from Professor Morgenstern who oversaw all of my laboratory activities and perhaps when I read the draft of Kratochwil 2016 for the first time.

Executed this 30 day of July, 2025.

M. Weis
Mirjam Weis
European Commission, Joint
Research Centre
Technical Assistant,
Mirjam.WEIS@ec.europa.eu